Back to team

Investment Team

Jean-François Formela, MD
Read Bio

Jean-François Formela is a partner and focuses on novel drug discovery approaches and therapeutics. He joined Atlas Venture in 1993 to build the U.S. life sciences franchise.

He is a director and co-founder of IFM Therapeutics and Korro Bio. Jean-François also serves on the boards of Ikena Oncology (NASDAQ: IKNA), Scorpion Therapeutics, and Triveni Bio, as well as several stealth companies.

His prior investments include Adnexus (acquired by BMS), ArQule (NASDAQ: ARQL, acquired by Merck), Arteaus Therapeutics (acquired by Eli Lilly), CoStim Pharmaceuticals (acquired by Novartis), Exelixis (NASDAQ: EXEL), Horizon Therapeutics (NASDAQ: HZNP), and NxStage (NASDAQ: NXTM, acquired by Fresenius). He was also a co-founder and director of Intellia Therapeutics (NASDAQ: NTLA) and Translate Bio (NASDAQ: TBIO, acquired by Sanofi).

Jean-François is a member of the Mass General Brigham Innovation Advisory Board and a former trustee of the Boston Institute of Contemporary Art. He received his M.D. from Paris University School of Medicine and his M.B.A. from Columbia University.

Connect on socials

It takes everyone to build a biotech and develop a drug. Discover our team.